Elaine’s group discovered a cardiac glycoside restrains EGFR-related and EGFR-independent NSCLC cell proliferation with distinct treatment mechanism
Non-small cell lung cancer (NSCLC) is the predominant histological type of lung cancer and is characterized by the highest mortality and incidence rates among these types of malignancies (1, 2). Traditional Chinese medicine (TCM) has been applied for centuries in China (3, 4). Cardiac glycosides, a class of natural products, have been identified as a potential type of chemotherapeutic agent (5, 6).
Lung Cancer Treatment Seminar
Seminar on lung cancer treatment update was held in Crown Plaza Hotel Macau. The featured speakers included Dr. Tongyu Lin and Dr. Cheng Huang.
Novel Direct AMPK Activator Suppresses Non-Small Cell Lung Cancer through Inhibition of Lipid Metabolism
Dr Elaine Lai-Han Leung et al reported that a new AMPK agonist can specifically supress non-small cell lung cancer resistant cells viability by inhibition of lipid metabolism.